TBPH 是一种溴化阻燃剂,在非酒精性脂肪性肝炎 (NASH) 小鼠中可增强肝脏脂肪变性、炎症和纤维化,诱导磷脂代谢失调并降低心磷脂 (CL) 和磷脂酰丝氨酸 (PS) 水平,导致内质网-线粒体 (ER-Mito) 接触受损及随后的线粒体功能障碍,并通过线粒体衍生的 ds-DNA 介导的炎症反应诱导肺损伤,因此可用于研究 MFN2 介导的内质网-线粒体接触在脂质代谢稳态中的作用。
产品编号: MS-H67524 纯度: 95.0% CAS No.: 26040-51-7 分子式: C24H34Br4O4 分子量: 706.14
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

TBPH 是一种溴化阻燃剂,在非酒精性脂肪性肝炎 (NASH) 小鼠中可增强肝脏脂肪变性、炎症和纤维化,诱导磷脂代谢失调并降低心磷脂 (CL) 和磷脂酰丝氨酸 (PS) 水平,导致内质网-线粒体 (ER-Mito) 接触受损及随后的线粒体功能障碍,并通过线粒体衍生的 ds-DNA 介导的炎症反应诱导肺损伤,因此可用于研究 MFN2 介导的内质网-线粒体接触在脂质代谢稳态中的作用。

生物实验数据

生物活性 TBPH is a brominated flame retardant that enhances hepatic steatosis, inflammation, and fibrosis in nonalcoholic steatohepatitis (NASH) mice, induces phospholipid metabolic dysregulation with reduced cardiolipin (CL) and phosphatidylserine (PS) levels, leads to impaired endoplasmic reticulum-mitochondria (ER-Mito) contacts and subsequent mitochondrial dysfunction, and induces lung injury through mitochondrial-derived ds-DNA-mediated inflammatory responses, and thus can be used to study the role of MFN2-mediated ER-Mito contacts in lipid metabolic homeostasis.
体外研究
(In Vitro)

TBPH (5-50 μM,48 小时) 通过破坏 NASH LO 模型中 MFN2 调节的 ER-Mito 接触来促进 NASH 进展。
TBPH (0-20 μg/mL,48 小时) 在 TC-1 和 BEAS-2B 细胞中降低细胞增殖能力,引起氧化应激,增加肺组织纤维化,导致肺线粒体释放 ds-DNA,从而激活 c-GAS-STING。

RT-PCR

Cell Line: NASH LOs model
Concentration: 5 μM, 50 μM
Incubation Time: 48 h
Result: Upregulated the transcriptional levels of oxidative stress-related genes (CYP2E1 and CYP1A2), fibrosis-related genes (COL3A1, COL4A1, LOXL2, TIMP1, VIM), and inflammation-related genes (TNF-α, IL-8).

Immunofluorescence

Cell Line: NASH LOs model
Concentration: 5 μM, 50 μM
Incubation Time: 48 h
Result: Decreased colocalization of mitochondria (HSP60) and ER (GRP78), indicating reduced ER-Mito contacts.

Western Blot Analysis

Cell Line: NASH LOs model
Concentration: 5 μM, 50 μM
Incubation Time: 48 h
Result: Decreased MFN2 level, increased UPRmt markers (HSP60, SOD2) and ER stress markers (GRP78, ATF6).

Western Blot Analysis

Cell Line: TC-1 and BEAS-2B cells
Concentration: 0 μg/mL, 0.2 μg/mL, 2 μg/mL, 10 μg/mL
Incubation Time: 48 h
Result: Inhibited the expression of CyclinD1 and promoted the phosphorylation of Rb, increased the expression levels of CDK2/4 and P53.
Increased the levels of IL-6, IL-1β, p-IκB and p-P65.
Up-regulated the expression of FN and α-SMA, Down-regulated the expression of E-cadherin.
体内研究
(In Vivo)

TBPH (20-200 mg/kg,灌胃,每日一次,4 周) 在蛋氨酸胆碱缺乏 (MCD) 饮食诱导的 NASH 小鼠模型中可增强肝脏脂质蓄积和代谢功能障碍,加速肝脏炎症反应和纤维化进展,破坏肝脏磷脂稳态和肝细胞内质网-线粒体接触,诱导肝脏线粒体功能障碍和内质网应激。
TBPH (20-200 mg/kg,灌胃,每日一次,4 周) 在正常饮食 (ND) 小鼠模型中不会改变肝脏形态,也不会改变肝体指数,但会损害肝细胞内质网-线粒体接触,诱导的线粒体功能障碍和内质网应激。
TBPH (0-100 μg/mL,灌胃,每天一次,4 周) 对 C57 小鼠的肺细胞造成氧化损伤,并引发肺细胞和组织的炎症反应。

Animal Model: MCD diet-induced NASH mouse (Male C57BL/6, 8-9 weeks old, 22-25 g) model
Dosage: 20 mg/kg, 200 mg/kg
Administration: i.g., once a day, 4 weeks
Result: Exacerbated hepatic pathology, increased the hepatosomatic index, enhanced lipid accumulation, decreased serum HDL and CHO levels, alongside elevated hepatic TG and serum LDL levels.
Augmented hepatic steatosis and inflammatory cell infiltration, enhanced fibrotic deposition, increased steatosis, inflammatory infiltration, fibrosis and NASH scores, elevated serum levels of AST and ALT.
Reduced the abundance of cardiolipin (CL), phosphatidylserine (PS), and phosphatidylethanolamine (PE), while increasing phosphatidic acid (PA) levels.
Disrupted lipid metabolism associated with the endoplasmic reticulum and mitochondria, altered the negative intrinsic curvature of membranes.
Reduced colocalization of ER and mitochondria in liver tissues, increased the physical distance between ER and mitochondria and reduced contact sites.
Caused a marked reduction in mitochondrial cristae, disrupted cristae junctions (CJs), and disorganization of cristae membranes in hepatocytes, reduced overall oxygen consumption and ATP content.
Increased HSP60, SOD2, mitochondrial proteases (LONP1, ClpP), GRP78, Atf6, eIF2α, and Chop levels, decreased the MFN2 protein level.
Animal Model: ND mice (Male C57BL/6, 8-9 weeks old, 22-25 g) model
Dosage: 20 mg/kg, 200 mg/kg
Administration: i.g., once a day, 4 weeks
Result: Did not significantly alter liver morphology, did not change the hepatosomatic index.
Affected C14:0 metabolism, fatty acids with 13-15 carbon chains, and mitochondrial metabolic processes, altered the negative intrinsic curvature of membranes.
Reduced colocalization of ER and mitochondria in liver tissues, increased the physical distance between ER and mitochondria and reduced contact sites.
Elevated the protein levels of mitochondrial chaperone HSP60, SOD2, GRP78, Atf6, eIF2α, and Chop, decreased the MFN2 protein level.
Animal Model: C57 mice model
Dosage: 0 μg/mL, 0.5 μg/mL, 1 μg/mL, 5 μg/mL, 10 μg/mL, 30 μg/mL L, 60 μg/mL, 100 μg/mL
Administration: i.g., once a day, 4 weeks
Result: Induced capillary congestion in the alveolar wall and obvious inflammatory cell infiltration.
Increased the expression levels of TNFα, IL-1β, IL-6, IL-8, IFNγ, eotaxin, MCP-1, MIP-2, RANTES, p16, p21, P65, and p-IκB proteins, and decreased the expression level of cell proliferation marker (Ki67).
Up-regulated the expression of FN, α-SMA, and TGF-β, down-regulated the expression of E-cadherin, and increases the content of collagen fibers in the lungs.
Increased ROS and MDA levels, and decreased GSH, SOD, and CAT expression levels.
性状 液体(密度:1.529±0.06 g/cm3)
颜色 Light yellow to yellow

化学信息

分子量 706.14
分子式 C24H34Br4O4
CAS No. 26040-51-7

储存&溶解度

储存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 175 mg/mL (247.83 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.4161 mL7.0807 mL14.1615 mL35.4037 mL
5 mM0.2832 mL1.4161 mL2.8323 mL7.0807 mL
10 mM0.1416 mL0.7081 mL1.4161 mL3.5404 mL
15 mM0.0944 mL0.4720 mL0.9441 mL2.3602 mL
20 mM0.0708 mL0.3540 mL0.7081 mL1.7702 mL
25 mM0.0566 mL0.2832 mL0.5665 mL1.4161 mL
30 mM0.0472 mL0.2360 mL0.4720 mL1.1801 mL
40 mM0.0354 mL0.1770 mL0.3540 mL0.8851 mL
50 mM0.0283 mL0.1416 mL0.2832 mL0.7081 mL
60 mM0.0236 mL0.1180 mL0.2360 mL0.5901 mL
80 mM0.0177 mL0.0885 mL0.1770 mL0.4425 mL
100 mM0.0142 mL0.0708 mL0.1416 mL0.3540 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用,-20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础